Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC)
has improved pathological responses and survival rates compared with chemotherapy …

Peripheral T-cell lymphoma (PTCL) is a clinically aggressive disease, with a poor response
to therapy and a low overall survival rate of approximately 30% after 5 years. We have …

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease whose prognosis is
associated with clinical features, cell-of-origin and genetic aberrations. Recent integrative …

Simple Summary Lymphoma research is a paradigm of integrating basic and applied
research within the fields of molecular marker-based diagnosis and therapy. In recent years …

Cancer-derived small extracellular vesicles (sEVs) are capable of modifying tumor
microenvironment and promoting tumor progression. Ovarian cancer (OvCa) is a lethal …

Purpose: Follicular lymphoma (FL) is the most frequent indolent non-Hodgkin lymphoma.
Around 20% of patients suffer early disease progression within 24 months (POD24) of …

Circulating recombinant forms (CRFs) contribute substantially to the HIV-1 pandemic.
Among 105 CRFs described in the literature, 16 are BF intersubtype recombinants, most of …

Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma
subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but …

The endocannabinoid system (ECS), a signalling network with immunomodulatory
properties, is a potential therapeutic target in multiple sclerosis (MS). Dimethyl fumarate …

Introduction: Peripheral T-cell lymphomas (PTCLs) are aggressive tumours with
unfavourable prognosis, with around 30% OS after 5 years. Histological and molecular …